Cell-based therapies for myocardial repair: Emerging role for bone marrow-derived mesenchymal stem cells (MSCs) in the treatment of the chronically injured heart

Methods in Molecular Biology

Volumn 1037, Issue , 2013, Pages 145-163

  Da Silva, Jose S ^a   Hare, Joshua M ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

BM MSC; cGMP; cGTP; CMC; FDA; HCT P; HF; IND; MI

Indexed keywords

ARTICLE; BONE MARROW TRANSPLANTATION; CELL CULTURE; CELL ISOLATION; CRYOPRESERVATION; FOOD AND DRUG ADMINISTRATION; HEART FAILURE; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THAWING; TISSUE REPAIR;

ANIMALIA; SUIDAE;

ANIMALS; CELL SEPARATION; CELL- AND TISSUE-BASED THERAPY; CHRONIC DISEASE; CRYOPRESERVATION; HEART DISEASES; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; PRIMARY CELL CULTURE; SWINE;

EID: 84934439637     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-505-7_8     Document Type: Article

References (37)

1. Ratcliffe E, Thomas RJ, Williams DJ (2011) Current understanding and challenges in bioprocessing of stem cell-based therapies for regenerative medicine. Br Med Bull 100(1):137-155
2. Astori G et al (2010) Bone marrow derived stem cells in regenerative medicine as advanced therapy medicinal products. Am J Transl Res 2(3):285-295
3. Bach FH et al (1968) Bone-marrow transplantation in a patient with the Wiskott-Aldrich syndrome. Lancet 2(7583):1364-1366
4. Gatti RA et al (1968) Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet 2(7583):1366-1369
5. Deans RJ, Moseley AB (2000) Mesenchymal stem cells: biology and potential clinical uses. Exp Hematol 28(8):875-884
6. Williams AR et al (2011) Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling. Circ Res 108(7):792-796
7. Kemp KC, Hows J, Donaldson C (2005) Bone marrow-derived mesenchymal stem cells. Leuk Lymphoma 11(46):1531-1544
8. Togel F, Westenfelder C (2007) Adult bone marrow-derived stem cells for organ regeneration and repair. Dev Dyn 236(12):3321-3331
9. Biehl JK, Russell B (2009) Introduction to stem cell therapy. J Cardiovasc Nurs 24(2):98-103
10. Boyle AJ, McNiece IK, Hare JM (2010) Mesenchymal stem cell therapy for cardiac repair. Methods Mol Biol 660:65-84
11. Husnain K, Haider MA (2004) Bone marrow cell transplantation in clinical perspective. J Mol Cell Cardiol 38:225-235
12. Muller YD et al (2011) Transplantation tolerance: clinical potential of regulatory T cells. Self Nonself 2(1):26-34
13. Christoforou N, Gearhart JD (2007) Stem cells and their potential in cell-based cardiac therapies. Prog Cardiovasc Dis 49(9):396-413
14. Kajstura J et al (2005) Bone marrow cells differentiate in cardiac cell lineages after infarction independently of cell fusion. Circ Res 96(1):127-137
15. Nunes SS et al (2011) Stem cell-based cardiac tissue engineering. J Cardiovasc Transl Res 4(5):592-602
16. Kanashiro-Takeuchi RM, Schulman IH, Hare JM (2011) Pharmacologic and genetic strategies to enhance cell therapy for cardiac regeneration. J Mol Cell Cardiol 51(4):619-625
17. Schuleri KH et al (2009) Autologous mesenchymal stem cells produce reverse remodelling in chronic ischaemic cardiomyopathy. Eur Heart J 30(22):2722-2732
18. http://clinicaltrials.gov/ct2/show/NCT005 87990?term= NCT00587990&rank=1
19. Hare JM (2009) Translational development of mesenchymal stem cell therapy for cardiovascular diseases. Tex Heart Inst J 36(2):145-147
20. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research (2008) Guidance for FDA reviewers and sponsors. Content and review of chemistry, manufacturing, and control (CMC) information for human somatic cell therapy investigational new drug applications (INDs)
21. 21 CFR 312.23(a)(7)(iv)(b)
22. 21 CFR 1271
23. 9 CFR 113.53
24. 21 CFR 211.84(a)
25. 21 CFR 610.12
26. United States Pharmacopeia (USP) <71> Sterility tests
27. CBER (1993) Points to consider in the characterization of cell lines used to produce biologicals
28. 21 CFR 600.3(r)
29. 21 CFR 610.13
30. 21 CFR 610.9
31. FDA (1987) FDA guideline on validation of the Limulus Amebocyte Lysate (LAL) Test as end-product endotoxin test for human and animal parenteral drugs, biological products, and medical devices
32. 21 CFR 312.23(a)(7)(ii)
33. 21 CFR 1271.290(b)
34. 21 CFR 312.6(a)
35. 21 CFR 1271.250
36. 21 CFR 1271.90
37. FDA (1999) Guidance for industry: container closure systems for packaging human drugs and biologics; chemistry, manufacturing, and controls documentation, May 1999